BioLineRx Ltd.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Non-accelerated filer
State of Incorporation
Israel
Country
Israel
Business Address
2 HAMAAYAN STREET, MODI-IN, , ISRAEL
Mailing Address
2 HAMAAYAN STREET, MODI-IN, , ISRAEL
Phone
972-8-642-9100
Fiscal Year End
1231
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 3 Initial insider ownership report | March 31, 2026 | View on SEC |
| 3 Initial insider ownership report | March 31, 2026 | View on SEC |
| 3 Initial insider ownership report | March 31, 2026 | View on SEC |
| 3 Initial insider ownership report | March 31, 2026 | View on SEC |
| 3 Initial insider ownership report | March 30, 2026 | View on SEC |
| 3 Initial insider ownership report | March 30, 2026 | View on SEC |
| 3 Initial insider ownership report | March 27, 2026 | View on SEC |
| 20-F/A Foreign annual report amendment | March 27, 2026 | View on SEC |
| 6-K Foreign company current report | March 26, 2026 | View on SEC |
| 20-F Foreign company annual report | March 23, 2026 | View on SEC |
Annual Reports
20-F
March 23, 2026
- Significant investment in core biotech assets: $1.5M lab equipment & $11.7M intangible assets (Motixafortide, AGI-134).
- Strategic partnerships with potential for substantial future revenue, including up to $200M from Gloria Biosciences.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.